Intranasal Semax in Alzheimer’s disease — RU2384343C2
Nikolay F. Myasoedov, Svetlana I. Gavrilova, Yaroslav B. Kalyn, Igor V. Kolykhalov, Natalya M. Mikhailova, Natalya D. Selezneva, Olga N. Sokolova, Alexander S. Tiganov, Lyudmila A. Andreeva · 2010 · RU2384343C2 · patent family RU2384343C2
Published 2010-03-20.
Reported patent results
Reported findings
23/25 improved on the global assessment: 13 minimally and 10 moderately.
Uncontrolled before-and-after observations in 25 patients: 13 with mild and 12 with moderate dementia. The disclosure describes 18–20 mg/day of intranasal Semax and reports the same group across examples.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Overall clinical improvement | 23/25 improved on the global assessment: 13 minimally and 10 moderately. | |
| Cognitive scores | Mean MMSE improved by 2.4 points and ADAS-Cog improved by 4.9 points. | |
| Instrumental activities of daily living | The patent reports a 1.2-point improvement overall. |
The patent provides no concurrent placebo group. Changes cannot be separated from other influences, and the report does not establish treatment benefit.
Source for these results ↗ · Reviewed 2026-11-12
Patent claims and provenance
Use. Claims the use of Semax 1% nasal drops in Alzheimer’s disease.
The patent provides no concurrent placebo group. Changes cannot be separated from other influences, and the report does not establish treatment benefit.
- Publication
- RU2384343C2 ↗ · 2010-03-20
- Earliest priority / filing
- 2008-02-27 / 2008-02-27
- Original applicant / assignee
- Peptogen
- Indexed status
- Not shown; official status unverified · checked 2026-11-12
- Patent family
- Grouping identifier unavailable · family publications are related filings, not independent studies.
Original title, inventors and related publications
Intranasal Semax in Alzheimer’s disease
Inventors: Nikolay F. Myasoedov; Svetlana I. Gavrilova; Yaroslav B. Kalyn; Igor V. Kolykhalov; Natalya M. Mikhailova; Natalya D. Selezneva; Olga N. Sokolova; Alexander S. Tiganov; Lyudmila A. Andreeva.
For research and education. Consult a qualified clinician for medical advice.
Study limitations and source details
Study limitations
- The patent provides no concurrent placebo group. Changes cannot be separated from other influences, and the report does not establish treatment benefit.
- The patent provides no concurrent placebo group. Changes cannot be separated from other influences, and the report does not establish treatment benefit.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Available format: Original patent text and indexed metadata
Material reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Related publications may cover the same research program or participants.
Source access
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Source reviewed 2026-11-12.
Source type: Patent publication
Citation and original source
Original source: Nikolay F. Myasoedov, Svetlana I. Gavrilova, Yaroslav B. Kalyn, Igor V. Kolykhalov, Natalya M. Mikhailova, Natalya D. Selezneva, Olga N. Sokolova, Alexander S. Tiganov, Lyudmila A. Andreeva. Intranasal Semax in Alzheimer’s disease — RU2384343C2 RU2384343C2 · patent family RU2384343C2 2010.
Molekul research summary: https://molekul.io/research/patent-ru2384343c2. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry